The Covid-19 pandemic has had a transformative effect on every aspect of the healthcare landscape, perhaps nowhere more so than in drug development as pharma companies have raced to develop viable treatment options..
Gilead Sciences is one of these companies. With a 35-year history as a leader in virology spanning HIV and hepatitis drug development, an antiviral treatment for Covid-19 has been a major focus since the pandemic began in 2020. In an interview, Anu Osinusi, Gilead Sciences VP of clinical research for virology, talked about her background. She discussed how growing up in Nigeria and her experience in pharmaceutical industry R&D has shaped her perspective and unrelenting commitment to teamwork and collaboration to develop a treatment for Covid-19.
Listen to the episode here:
